Anzeige
Mehr »
Login
Sonntag, 21.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Hammer-Meldung! Löst diese Meldung den nächsten Hype aus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 885823 | ISIN: US3755581036 | Ticker-Symbol: GIS
Tradegate
19.04.24
21:43 Uhr
62,67 Euro
0,00
0,00 %
1-Jahres-Chart
GILEAD SCIENCES INC Chart 1 Jahr
5-Tage-Chart
GILEAD SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
62,5262,7817:22
62,6162,7319.04.
ACCESSWIRE
370 Leser
Artikel bewerten:
(2)

Gilead Sciences: Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

- 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead's Setting the P.A.C.E. Initiative -

FOSTER CITY, CA / ACCESSWIRE / February 28, 2024 / Gilead Sciences, Inc. (NASDAQ:GILD) announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. These grants are a part of Gilead's new Setting the P.A.C.E. (Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic.

In 2021, Black women accounted for 53% of new HIV diagnoses among women aged 16 and older in the United States, despite comprising only 14% of the women living in the country. Additionally, Black Transgender women have the highest rates of new HIV diagnoses among Transgender people and are more likely to go undiagnosed and untreated in comparison to their peers. These inequities are exacerbated by significant gaps in the delivery of effective and culturally relevant HIV prevention information and care services for Black women and girls.

"By taking a strategic, community-centered approach to address systemic disparities and improve overall health outcomes, Gilead continues its commitment to advancing health equity for Black cisgender and Transgender women and girls in the U.S. who continue to be disproportionately impacted by the HIV epidemic," said Deborah H. Telman, Executive Vice President, Corporate Affairs and General Counsel, Gilead Sciences. "Gilead's Setting the P.A.C.E. initiative will help empower organizations to expand custom programs tailored toward fighting stigma and expanding access to HIV care in their communities."

Through this investment, Setting the P.A.C.E. grantee organizations will develop and support a variety of impactful projects to help improve health outcomes for Black women and girls, from expanding programs that provide culturally-responsive HIV care training, to leveraging arts and media to engage local communities and address stigma. Importantly, more than 75% of the organizations selected for grants are led by Black women and every funding allocation is directed toward initiatives led or co-led by Black women. Additionally, the states in which programming will be implemented align with states that have higher numbers of Black women living with HIV.

"Gilead's Setting the P.A.C.E. grant marks a pivotal moment for Ribbon and the communities we serve across the nation," said Linda H. Scruggs, Co-Executive Director, Ribbon. "Gilead's support enables us to form collaborative partnerships and programs to help end the disparities in HIV awareness, prevention and care. Our focus on the intersection of Black cisgender and Transgender women in relation to HIV is not just about addressing an unmet need, it's about rewriting narratives and changing destinies. Ribbon is dedicated to creating a future where access to HIV education and resources is a right, not a privilege, and where every person, regardless of their identity, can live a life of health, dignity and opportunity."

The 19 Gilead Setting the P.A.C.E. grantees are:

  • A New Way of Life Reentry Project (Los Angeles, California)
  • AIDS United (Washington, D.C.)
  • Baltimore Safe Haven (Baltimore, Maryland)
  • California Black Women's Health Project (Inglewood, California)
  • Dancing Grounds (New Orleans, Louisiana)
  • Foundations for Living Incorporated (Jefferson, Georgia)
  • Howard University (Washington, D.C.)
  • National Association of Black Social Workers (Washington, D.C.)
  • Power Safe Place Resource Center of Virginia (Front Royal, Virginia)
  • Ribbon, Inc. (Largo, Maryland)
  • San Francisco Community Health Center (San Francisco, California)
  • SisterLove, Inc. (Atlanta, Georgia)
  • SLK Health Services Corporation (Lanham, Maryland)
  • The Black Women's Learning Institute (BWLI) at NDRI-USA, Inc. (New York, New York)
  • Transinclusive Group (Pembroke Pines, Florida)
  • Triumphant Together (Kissimmee, Florida)
  • Unspoken Treasure Society (Gainesville, Florida)
  • Waco Theater Center (Hollywood, California)
  • WeCareTn (Memphis, Tennessee)

Gilead's Setting the P.A.C.E. initiative aims to empower local organizations to address ongoing health inequities in care and treatment through four key programmatic areas: HIV prevention, arts and advocacy, community and education. The program builds on Gilead's longstanding commitment toward investing in Black women's health and leadership through philanthropy. In addition to this new funding, the company has provided more than $35.8 million in philanthropic support for Black women-led and/or Black women-serving organizations in the United States since 2017. More than $28 million of those investments were granted to organizations working to help end the HIV epidemic.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Jacquie Ross, Investors

Investor_relations@gilead.com

Meaghan Smith, Media

Public_affairs@gilead.com

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View the original press release on accesswire.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2024 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.